Groundbreaking HIV prevention drug shows 100% efficacy

By Shola Ogundipe A promising new HIV prevention drug called lenacapavir has shown 100 percent efficacy in a clinical trial among adolescent girls and young women in South Africa and Uganda. The twice-yearly injection was found to be superior to daily Truvada, the current standard for pre-exposure prophylaxis (PrEP). This is according to Gilead Sciences, the developer of lenacapavir. In a release signed by Kay Marshall, Senior Communications Advisor for AVAC, the organization welcomes the groundbreaking results of the PURPOSE 1 study which enrolled over 5,300 cisgender adolescent girls and young women between the age of 16 and 26 in…